Race Oncology Ltd (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Race Oncology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$234.53 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
173.73 million
Earnings per share
-0.047
Dividend per share
N/A
Year To Date Return
-1.48%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Race Oncology Ltd (ASX: RAC)
Latest News
Share Gainers
3 ASX biotech shares rocketing 10% to 26% on BIG news!
Healthcare Shares
ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest
Healthcare Shares
2 ASX healthcare shares having a stellar run today
Share Gainers
Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today
Earnings Results
Two up, one down: ASX healthcare stocks split after FY24 results
Healthcare Shares
2 ASX healthcare shares outperforming on big news
Share Gainers
Why A2 Milk, Actinogen Medical, Karoon Energy, and Race Oncology shares are rising
Healthcare Shares
Guess which ASX healthcare stock is surging 15% on a 'major milestone'
52-Week Highs
3 ASX healthcare shares smashing new 52-week highs today
Share Gainers
Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher
Healthcare Shares
ASX healthcare stock surges 11% on 'incredibly valuable' FDA news
Share Gainers
Why Arizona Lithium, Bapcor, Race Oncology, and Tower shares are pushing higher
Frequently Asked Questions
-
No, Race Oncology does not pay dividends at this time.
-
Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Race Oncology Ltd
Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.
Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.
The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).
As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.
RAC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 May 2025 | $1.35 | $0.02 | 1.50% | 301,646 | $1.41 | $1.49 | $1.34 |
| 12 May 2025 | $1.33 | $0.09 | 7.23% | 409,319 | $1.26 | $1.42 | $1.25 |
| 09 May 2025 | $1.25 | $0.02 | 1.63% | 134,171 | $1.24 | $1.28 | $1.22 |
| 08 May 2025 | $1.23 | $0.06 | 5.15% | 77,695 | $1.20 | $1.25 | $1.19 |
| 07 May 2025 | $1.17 | $-0.01 | -0.85% | 58,608 | $1.18 | $1.20 | $1.17 |
| 06 May 2025 | $1.18 | $0.05 | 4.42% | 69,030 | $1.14 | $1.19 | $1.12 |
| 05 May 2025 | $1.13 | $-0.08 | -6.61% | 134,048 | $1.21 | $1.23 | $1.12 |
| 02 May 2025 | $1.21 | $0.01 | 0.83% | 136,913 | $1.25 | $1.26 | $1.21 |
| 01 May 2025 | $1.20 | $0.16 | 15.31% | 471,539 | $1.10 | $1.26 | $1.10 |
| 30 Apr 2025 | $1.05 | $0.00 | 0.00% | 42,398 | $1.05 | $1.08 | $1.04 |
| 29 Apr 2025 | $1.05 | $0.04 | 4.00% | 131,722 | $0.99 | $1.07 | $0.99 |
| 28 Apr 2025 | $1.00 | $-0.01 | -0.99% | 67,607 | $1.02 | $1.03 | $1.00 |
| 24 Apr 2025 | $1.02 | $0.05 | 5.21% | 125,771 | $0.98 | $1.03 | $0.97 |
| 23 Apr 2025 | $0.96 | $0.00 | 0.00% | 68,221 | $0.98 | $0.99 | $0.95 |
| 22 Apr 2025 | $0.96 | $0.03 | 3.24% | 85,281 | $0.93 | $1.00 | $0.93 |
| 17 Apr 2025 | $0.93 | $-0.02 | -2.11% | 98,001 | $0.95 | $0.98 | $0.92 |
| 16 Apr 2025 | $0.95 | $-0.05 | -5.00% | 36,353 | $1.00 | $1.00 | $0.95 |
| 15 Apr 2025 | $1.00 | $0.02 | 2.04% | 182,268 | $0.98 | $1.00 | $0.94 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Nov 2024 | Serge Scrofani | Issued | 58,446 | $82,408 |
Issue of options.
|
| 30 May 2024 | Mary Harney | Exercise | 1,170 | $877 |
Exercise of options.
|
| 30 May 2024 | Mary Harney | Issued | 1,170 | $877 |
Exercise of options.
|
| 30 May 2024 | Mary Harney | Issued | 3,510 | $5,036 |
Issue of options.
|
| 23 May 2024 | Phillip(Phil) Lynch | Issued | 21,457 | $16,092 |
Exercise of options.
|
| 23 May 2024 | Phillip(Phil) Lynch | Exercise | 21,457 | $16,092 |
Exercise of options.
|
| 23 May 2024 | Phillip(Phil) Lynch | Issued | 64,371 | $93,659 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Megan Baldwin | Non-Executive Director | Jan 2025 |
Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She is the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases. Her experience includes 10 years as CEO and Managing Director of Opthea. Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentechs commercial division. Dr Baldwins experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentechs early stage oncology programs. Dr Baldwin has corporate governance experience and currently serves on the boards of Anaxis Pharma and Gertrude Biomedical, and is a director of Ausbiotech.
|
| Dr Daniel Tillett | Chief Executive OfficerManaging Director | Sep 2019 |
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology, pharmacy, microbiology and virology.
|
| Dr Peter (Pete) Smith | Executive DirectorExecutive Chairman | Jun 2023 |
Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a Pharmaceuticals Analyst with UBS and HSBC, being involved in transactions including LSE/NASDAQ initial public offerings, fundraisings, and mergers & acquisitions (M&A). He is also currently a Director of MycRx Inc. and Amala Therapeutics.
|
| Dr Serge Scrofani | Non-Executive Director | Sep 2024 |
Dr Scrofani has more than 28 years experience in the healthcare sector, working in global roles across research, strategy and corporate development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives. Prior to this, he led Business Development for CSL Behring based in the US. Serge is currently Principal of Poplar Advisory, a boutique strategic advisory firm focused on the healthcare sector. He is also a Board member of the Burnet Institute and The Centre for Eye Research, and a founding Director of the private equity firm FinCap Pty Ltd.
|
| Mr Peter Webse | Company Secretary | Aug 2016 |
-
|
| Michelle Rashford | Chief Medical Officer |
-
|
|
| Peter Webse | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Dr Daniel Tillett | 17,267,615 | 10.13% |
| Mr Phillip Richard Perry | 6,334,328 | 3.72% |
| Mr Mark Phillip Juan | 5,839,062 | 3.43% |
| The Trust Company (Australia) Limited <Mof A/C> | 5,147,246 | 3.02% |
| Biosynergy Partners Pty Ltd | 4,855,700 | 2.85% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient > | 2,618,464 | 1.54% |
| Marinella Messina | 1,845,245 | 1.08% |
| Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> | 1,669,500 | 0.98% |
| Mr Sandor Helby | 1,625,000 | 0.95% |
| Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> | 1,575,000 | 0.92% |
| Kudoss Investments Pty Ltd <Aitken Global Family A/C> | 1,500,000 | 0.88% |
| Mr Anthony James Robinson <The Peeko Family No 86 A/C> | 1,370,262 | 0.80% |
| Mr Alan Giles Sauran | 1,094,368 | 0.64% |
| Mr Brian James Walker | 955,000 | 0.56% |
| Pierpont Investments Pty Ltd <Pierpont Super Fund A/C> | 950,000 | 0.56% |
| Surpion Pty Ltd <M W Suhr & Co A/C> | 935,000 | 0.55% |
| Citicorp Nominees Pty Limited | 847,284 | 0.50% |
| Mr Van Quy Do | 829,409 | 0.49% |
| Mr Beau Thomas Robinson <Beau Robinson Invstmnt A/C> | 743,458 | 0.44% |
| Mr Graeme Stewart Pocknall & Mrs Vivienne Glynis Pocknall | 674,511 | 0.40% |
